Development and validation of a risk prediction model and management strategy for red blood cell irregular antibodies a retrospective cohort study of 521 patients

红细胞异常抗体风险预测模型及管理策略的建立与验证:一项纳入521例患者的回顾性队列研究

阅读:2

Abstract

This study aimed to systematically identify independent risk factors for difficult cross-matching and to construct a predictive model for early clinical risk warning and stratified management. A derivation cohort of 521 patients with positive red blood cell irregular antibody screening results was retrospectively enrolled. Based on the screening results, patients were categorized into a 1-2 positive wells group (n = 428) and a 3 positive wells group (n = 93). Univariate and multivariate logistic regression analyses were performed to identify independent predictors of difficult cross-matching. A simplified clinical risk scoring system was developed based on the regression coefficients, and the predictive performance of the model was evaluated. Multivariate analysis identified six independent influencing factors: 3 positive wells (OR = 2.34, 95% CI: 1.18-4.65), diagnosis of multiple myeloma (OR = 5.05, 95% CI: 2.54-10.05), hospitalization in the hematology department (OR = 2.25, 95% CI: 1.27-3.98), age ≥ 60 years (OR = 1.97, 95% CI: 1.12-3.48), pregnancy-related diseases (protective factor; OR = 0.24, 95% CI: 0.08-0.73), and difficult blood typing (OR = 4.57, 95% CI: 2.30-9.08). The risk scoring model incorporating these factors demonstrated good predictive performance, with an area under the curve (AUC) of 0.819 (95% CI: 0.766-0.872), a sensitivity of 74.4%, and a specificity of 76.5%. Patients were stratified into three risk tiers (low, medium, and high) based on their scores, with corresponding differentiated clinical management pathways and resource allocation plans established. This study successfully identified and quantified key clinical and laboratory predictors for difficult cross-matching. The established risk scoring model demonstrates good predictive accuracy, providing a reliable tool for precise pre-transfusion risk assessment. The stratified management system based on this model facilitates a shift from reactive to proactive intervention in transfusion workflows, offering significant clinical translational value for optimizing blood bank resource allocation and ensuring transfusion safety for high-risk patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。